- Home
- CTO vs CATX Comparison
CTO vs CATX Comparison
Compare CTO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | CATX |
|---|---|---|
| Founded | 1902 | 1983 |
| Country | United States | United States |
| Employees | 42 | 166 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 497.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CTO | CATX |
|---|---|---|
| Price | $19.14 | $4.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $21.50 | $12.11 |
| AVG Volume (30 Days) | 177.5K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | $12.71 |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $1.60 |
| 52 Week High | $20.25 | $6.16 |
Technical Indicators
Market Signals| Indicator | CTO | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 45.41 |
| Support Level | $17.14 | $3.24 |
| Resistance Level | $19.82 | $4.64 |
| Average True Range (ATR) | 0.33 | 0.33 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 89.52 | 42.39 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.